Drug intelligence / Profile preview

aTRPV1

Development stage: Preclinical
Lead developer: Oblique Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral

Overview

aTRPV1 is a monoclonal antibody developed by Oblique Therapeutics for the treatment of pain. It targets the Transient Receptor Potential Vanilloid 1 (TRPV1) ion channel, a key mediator of pain signaling in response to thermal and chemical stimuli. Developed using the company's proprietary Abiprot platform, aTRPV1 is designed to selectively modulate the channel's activity, potentially overcoming the clinical limitations of small-molecule TRPV1 antagonists, such as hyperthermia and impaired noxious heat sensation. The program is currently in preclinical development.

Other names: anti-TRPV1 antibodyanti-TRPV-1 antibodyanti-TRPV 1 antibody

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on aTRPV1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aTRPV1.

Explore the full profile